

[Policy Review Information](#)

[Preventive Services Information](#)

What's New:

5/15/2019

Revised MCGs:

1. [Ado-trastuzumab emtansine \(Kadcyla\)](#) - Review and revision to guideline; updated description, position statement, references.
2. [Agalsidase Beta \(Fabrazyme\) IV](#) - Review and revision to guideline consisting of updating the position statement, precautions, and references.
3. [Automated Percutaneous Discectomy, Laser Discectomy, Percutaneous Endoscopic Discectomy, and DISC Nucleoplasty](#) - Unscheduled review. Revised description. Maintained position statement and updated references.
4. [Binimetinib \(Mektovi\) Tablet](#) - Revision to guideline; consisting of updating position statement, coding and references.
5. [Blinatumomab \(Blincyto\) IV](#) - Review and revision; consisting of updating position statement, references.
6. [Botulinum Toxins](#) - Revision to guideline consisting of updating the position statement.
7. [Breast Ductoscopy](#) - Review; Position statement maintained and references updated.
8. [Cannabidiol \(Epidiolex\)](#) - Review and revision to guideline; updated references
9. [Cenegermin-bkbj \(Oxervate\)](#) - Review and revision to guideline consisting of updating the description section, position statement, and references.
10. [Certolizumab Pegol \(Cimzia\) Injection](#) - Revision to guideline consisting of updating the description section and dosage/administration section based on the new FDA-approved indication of non-radiographic axial spondyloarthritis.
11. [Clotting Factors and Coagulant Blood Products](#) - Review and revision to guidelines; consisting of updating position statement and references.
12. [Corticosteroid Intravitreal Implant](#) - Review and revision to guideline consisting of updating the references.
13. [Dabrafenib \(Tafinlar\) Capsules](#) - Revision to guideline; consisting of updating position statement, coding and references.
14. [Ductal Lavage and Suction Collection Systems](#) - Review; Position statement maintained and references updated.
15. [Dupilumab \(Dupixent\) Injection](#) - Revision to guideline consisting of updating the description section, position statement, and references.
16. [Reconstructive Surgery Cosmetic Surgery](#) - Revised statement for scar surgery; added "treatment". Added statement for treatment of keloid(s). Revised statement for skin lesions. Updated references.
17. [Encorafenib \(Braftovi\) Capsule](#) - Revision to guideline; consisting of updating position statement, coding and references.
18. [Eribulin Mesylate \(Halaven\) Injection](#) - Review and revision; updated description, references.

19. [Erythropoiesis Stimulating Agents](#) - Review and revision to guideline; consisting of updating position statement, dosing and references.
20. [Fosnetupitant-Palonosetron \(Akynzeo\) IV](#) - Review and revision to guideline consisting of updating Table 1 and references.
21. [Gender Reassignment Surgery](#) - Review; Position maintained; description, position statements, and references updated.
22. [Genetic Testing](#) - Revision; Position statements, including testing for dilated cardiomyopathy, and references updated.
23. [Granisetron \(Sustol\) injection](#) - Review and revision to guideline; consisting of updating position statement, Table 1, and references.
24. [Human EGFR Inhibitors \(Cetuximab \[Erbix\], Panitumumab \[Vectibix\]\)](#) - Revision to guideline; consisting of updating the position statement, coding and references.
25. [Investigational Services](#) - Deleted code 0080U (refer to policy 05-86000-22).
26. [Ipilimumab \(Yervoy\) Injection](#) - Review and revision to guideline; consisting of revising position statement, description, coding and references.
27. [Ivacaftor \(Kalydeco\) Oral](#) - Review and revision to guideline; consisting of updating position statement and references.
28. [Keratoplasty and Keratectomy](#) - Revision: revised statement regarding epithelial-on method of corneal cross linking. Updated references.
29. [Larotrectinib \(Vitrakvi\)](#) - Revision to guideline; consisting of updating position statement, coding and references.
30. [Left Atrial Appendage Closure](#) - Scheduled review. Position statement maintained. Updated references.
31. [Lumacaftor Ivacaftor \(Orkambi\) Capsule](#) - Review and revision to guideline; consisting of updating position statement and references.
32. [Migalastat \(Galafold\)](#) - Review and revision to guideline consisting of updating the position statement and references.
33. [Minimally Invasive Procedures for Treatment of GERD and Dysphagia](#) - Deleted codes 43201, 43212, 43236, 43241, and 43266.
34. [Nab-Paclitaxel Injection \(Abraxane\)](#) - Revision to guideline; consisting of updating position statement, coding and references.
35. [Nivolumab \(Opdivo\)](#) - Review and revision to guideline; consisting of updating position statement, description, coding and references.
36. [NK-1 receptor antagonist injectable therapy \(Emend, Cinvanti, Varubi\)](#) - Review and revision to guideline consisting of updating Table 1 and references.
37. [Olaparib \(Lynparza\)](#) - Review and revision to guideline; consisting of updating position statement and references.
38. [Palivizumab \(Synagis\)](#) - Review and revision to guideline; consisting of updating references.
39. [Palonosetron Hydrochloride \(Aloxi\)](#) - Revision to Table 1 and references
40. [PCSK9 Inhibitors](#) - Review and revision to guideline consisting of updating the description section, position statement, other section, and references.
41. [Pembrolizumab \(Keytruda\) Injection](#) - Review and revision to guideline; consisting of updating position statement, description, coding and references.
42. [Pertuzumab \(Perjeta\) Injection](#) - Revision to guideline; consisting of updating position statement, references, coding.

43. [Pomalidomide \(Pomalyst\) Capsule](#) - Revision to guideline consisting of updating the description, position statement, billing/coding, and references based on a new NCCN recommended indication.
44. [Prosthetics](#) - Revision: Deleted coverage statement regarding mastectomy sleeves (L8010).
45. [Scanning Computerized Ophthalmic Diagnostic Imaging](#) - Scheduled review. Revised description, position statement, program exceptions, and index terms. Updated references.
46. [Signal Averaged Electrocardiography \(SAECG\)](#) - Review; Position statement maintained; description section and references updated.
47. [Sodium Oxybate \(Xyrem\) Oral](#) - Review and revision to guideline consisting of updating the description section, position statement, dosage/administration, precautions, and references.
48. [Technologies for the Evaluation of Malignant Melanoma](#) - Review; position statement maintained and references updated.
49. [Tezacaftor-Ivacaftor \(Symdeko\)](#) - Review and revision to guideline; consisting of updating references.
50. [Trametinib \(Mekinist\) Tablets](#) - Revision to guideline; consisting of updating position statement, coding, and references
51. [Transcatheter Aortic Valve Replacement](#) - Review; no change to position statement. Removed investigational from code (33363, 33364, 33365, 33368, 33369). Updated references.
52. [Transcranial Magnetic Stimulation](#) - Review; added memory (working) to experimental or investigational position statement. Added TMS (including high frequency deep transcranial magnetic stimulation (HF DTMS/HF dTMS) utilizing the Brainsway device (helmet) for the treatment of obsessive compulsive disorder (OCD) and all other indications. Updated references.
53. [Trastuzumab \(Herceptin\) Injection](#) - Review and revision; Updated description, references.
54. [Trifluridine-Tipiracil \(Lonsurf\) Capsule](#) - Revision to guideline consisting of updating position statement, coding and references
55. [Tumor Genetic Markers](#) - Revision; Serum Biomarker Human Epididymis Protein 4 position statement added; references updated.
56. [Tumor Treating Fields Therapy](#) - Scheduled review. Revised MCG title and description. Maintained position statement and updated references.
57. [Vascular Endothelial Growth Factor Inhibitors](#) - Review and revision to guideline consisting of updating the dosage/administration and references.
58. [Venetoclax \(Venclexta\) Tablet](#) - Revision to guideline consisting of updating the description, position statement, and references based on an FDA warning regarding off-label use in multiple myeloma.
59. [Vismodegib \(Erivedge\) Capsules](#) - Revision to guideline consisting of updating the description, position statement, billing/coding, and references based on new NCCN recommended indication.
60. [Voretigene Neparvovec-rzyl \(Luxturna\) Injection](#) - Review and revision to guideline consisting of updating the position statement and references.

Policy Review Information

Submit new information relevant to a policy when next reviewed by Florida Blue to:

Florida Blue Medical Policy Area

4800 Deerwood Campus Parkway

Building 900, 4th floor

Jacksonville, FL 32246-8273

Preventive Services Information

Preventive services include a broad range of services (including screening tests, counseling, and immunizations/vaccines). Florida Blue has adopted the U.S. Preventive Services Task Force (USPSTF) Guide to Clinical Preventive Services: [childhood and adolescent immunization schedule approved by: the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP); adult immunization schedule approved by: the Advisory Committee on Immunization Practices (ACIP), the American College of Obstetricians and Gynecologists (ACOG), and the American Academy of Family Physicians (AAFP)].

[Centers for Disease Control and Prevention \(CDC\)](#) (recommended vaccines and immunizations).

[Guide to Clinical Preventive Services](#) (recommendations made by the **USPSTF** for clinical preventive services).